GLP-1 Drugs Linked to Significantly Lower Risk of Knee Replacement Surgery

What the study found

Researchers analyzed anonymized medical records from the TriNetX Global Research Network, identifying adults with knee osteoarthritis diagnosed between January 1, 2010 and December 31, 2024. Patients who received GLP-1 receptor agonists were matched to untreated patients with similar characteristics — including age, sex, BMI, obesity-related conditions, and musculoskeletal diagnoses — using propensity score methods to reduce the influence of baseline differences between groups.

The need for total knee replacement surgery was then assessed at 1, 3, 5, and 8 years after diagnosis. The results were consistent across every time point: GLP-1 receptor agonist use was associated with significantly fewer knee replacements regardless of treatment duration.

The greatest effects were seen with the newest agents and the longest treatment duration. At the 8-year assessment, three years of treatment with semaglutide or tirzepatide was associated with a cumulative risk nearly five percentage points lower than in untreated patients.

Why the benefit may be more than just weight loss

Osteoarthritis is often framed as a mechanical problem — excess body weight places greater stress on knee joints, accelerating cartilage breakdown. Weight loss would therefore be an obvious pathway through which GLP-1 drugs might help. But the researchers and several outside commentators note that the story may be more complex than that.

Emerging evidence suggests GLP-1 receptor agonists have anti-inflammatory effects that could directly protect joint tissue, separate from their effect on weight. Animal models have shown these drugs may reduce synovial inflammation — the chronic joint inflammation that drives osteoarthritis progression — and may help preserve cartilage integrity.

This would mean GLP-1 drugs aren't just helping knees because patients weigh less. They may be modulating the biological environment inside the joint itself.

"Our findings align with evidence that GLP-1 receptor agonists may influence knee osteoarthritis through complementary anti-inflammatory and analgesic mechanisms," the researchers wrote.

How this study was done — and its limits

The study drew on records from 28,599 patients treated with newer GLP-1 receptor agonists for one year, and 13,351 treated for three years. Older GLP-1 agents were also assessed in larger groups. The dataset is large by the standards of this kind of research.

The authors are direct about the study's limitations. It is observational — meaning it can identify associations, not prove causation. Unmeasured variables such as frailty, physical activity level, functional capacity, and osteoarthritis severity weren't captured in the records. The data relied on prescription records, without independent confirmation that the drugs were actually taken.

"Accordingly, these findings should be interpreted as observational associations consistent with potential disease-modifying effects rather than evidence of causality," the researchers note.

The findings do not constitute a recommendation that GLP-1 drugs be used specifically to treat or prevent osteoarthritis. Prospective randomized trials would be needed to establish causation and guide clinical guidelines.

Why this matters for women

Knee osteoarthritis is not a condition that affects people equally. Women are more likely than men to develop osteoarthritis, and post-menopausal women face accelerated cartilage loss as estrogen levels decline. The condition is one of the leading drivers of disability in women over 50.

If GLP-1 drugs' joint benefits are confirmed in prospective trials, it could meaningfully change the calculus for women managing metabolic health in midlife — not just in terms of weight or cardiovascular risk, but as a potential strategy for joint preservation over the long term.

"If confirmed in prospective trials, these associations could shift treatment paradigms toward integrating metabolic health as a core component of joint preservation," the researchers concluded.

What GLP-1 receptor agonists are — and what they're currently approved for

GLP-1 receptor agonists are a class of drugs that mimic the action of glucagon-like peptide-1, a hormone released after eating that stimulates insulin secretion and reduces appetite. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two most widely prescribed members of this class in 2026.

Neither drug is currently FDA-approved for osteoarthritis. Their approved indications include type 2 diabetes, chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, and — as of 2025–2026 — non-alcoholic fatty liver disease (MASH). Use for osteoarthritis would currently be considered off-label.